Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. Additionally, the company will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event from January 11-14, 2021. Webcasts will be available on CytomX’s website, with archived replays accessible for 90 days post-conference. CytomX focuses on developing innovative Probody therapeutics for cancer, partnering with major pharmaceutical companies.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Mani Mohindru, PhD, to its board of directors. Dr. Mohindru, an experienced biotech executive, brings a strong background in finance and corporate strategy, previously serving as CEO of CereXis and CFO at Cara Therapeutics. Her expertise is expected to accelerate the development of CytomX's clinical pipeline, particularly its innovative Probody technology, aimed at creating selective cancer therapies. This leadership change comes as CytomX prepares for multiple critical data releases in 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to present two posters at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11. The presentations will focus on the clinical activity of CX-2009, a Probody drug conjugate, and its potential in treating advanced breast cancers. Notably, the data highlights the efficacy of CX-2009 alone and in combination with pacmilimab in HER2-non amplified breast cancer. The presentations occur on December 9 at 9:00 AM ET, showcasing CytomX's commitment to innovative cancer treatments.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., CEO, will participate in two virtual healthcare conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 18, 2020, at 10:15 a.m. ET. Additionally, the 32nd Annual Piper Sandler Virtual Healthcare Conference will occur on November 30, 2020, with a fireside chat available for on-demand viewing starting November 23, 2020, at 10:00 a.m. ET. Webcasts can be accessed on CytomX’s website with archived replays available for 90 days.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported its third quarter 2020 financial results, showing revenue of $17.8 million, a 66% increase from the same period in 2019. The company highlighted advancements in its clinical pipeline, including five Probody programs in the clinic, with four in Phase 2 studies. CX-2009 and CX-2029 are among the candidates being developed with initial data anticipated in late 2021. As of September 30, CytomX had $321.1 million in cash and equivalents, reflecting strong financial health.
CytomX Therapeutics (Nasdaq: CTMX) announced the initiation of a Phase 2 expansion study for CX-2029, a Probody drug conjugate targeting CD71, an important cancer target. This study will include various cancer types and is expected to enroll around 25 patients per cohort, focusing on overall response rate (ORR) and safety. The collaboration with AbbVie allows CytomX to earn up to $390 million in milestone payments. Initial data from the study is anticipated in late 2021, further showcasing CytomX's innovative approach to oncology.
CytomX Therapeutics (Nasdaq: CTMX) will announce its second quarter 2020 financial results on November 5, 2020, after U.S. market close. A teleconference will be held at 5:00 p.m. ET with a live audio webcast available on its website. CytomX focuses on developing investigational antibody therapeutics through its Probody technology, which aims to improve the efficacy and safety of cancer treatments. The company has established collaborations with major pharmaceutical entities to develop a pipeline of innovative therapeutics targeting difficult cancers.
CytomX Therapeutics (NASDAQ:CTMX) announces the retirement of W. Michael Kavanaugh, M.D., its Chief Scientific Officer, effective December 1, 2020. He will continue as an advisor on the Scientific Advisory Board. Marcia P. Belvin, Ph.D., is promoted to Senior Vice President, Head of Research, bringing nearly 20 years of oncology experience. CytomX focuses on developing Probody therapeutics, which selectively target tumors while minimizing toxicity to healthy tissues. The company's pipeline includes innovative candidates like CX-2009 and CX-2029, aimed at previously undruggable cancer targets.
CytomX Therapeutics (NASDAQ: CTMX) announced the granting of stock options to nine new employees on September 15, 2020. A total of 211,000 shares were issued at an exercise price of $7.22, equal to the closing price on that date. This action is part of the Company's 2019 Employment Inducement Incentive Plan, aimed at attracting talent. CytomX is a clinical-stage biopharmaceutical company focused on oncology, utilizing its Probody technology to develop innovative cancer treatments, partnering with major industry players like AbbVie and Bristol Myers Squibb.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two virtual healthcare conferences in September 2020. The events are the Citi’s 15th Annual BioPharma Virtual Conference on September 10, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 12:00 p.m. ET. A live audio webcast of the latter will be available on CytomX's website, with a 90-day archive. CytomX is pioneering a novel class of antibody therapeutics for cancer treatment, collaborating with major biotech firms to develop innovative therapies.